Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …

The generation of anti-tumor immunity in the draining lymph nodes is known as the cancer
immunity cycle. Accumulating evidence supports the occurrence of such a cycle at tumor …

Background Standard treatment with neoadjuvant nivolumab plus chemotherapy
significantly improves outcomes in patients with resectable non–small-cell lung cancer …

Therapeutic strategies harnessing the immune system to eliminate tumour cells have been
successfully used for several cancer types, including in patients with advanced-stage non …

Oncogenesis is associated with intestinal dysbiosis, and stool shotgun metagenomic
sequencing in individuals with this condition might constitute a non-invasive approach for …

Neoadjuvant chemoimmunotherapy improves pathologic complete response rate and event-
free survival in patients with resectable non–small cell lung cancer (NSCLC) versus …

Here, we summarize the current knowledge on eight promising drugs and natural
compounds that have been tested in the clinic: metformin, NAD+ precursors, glucagon-like …

With immune checkpoint inhibitors (ICIs) becoming the mainstay of treatment for many
cancers, managing their immune-related adverse events (irAEs) has become an important …

Antibodies targeting the immune checkpoint molecules PD-1, PD-L1 and CTLA-4,
administered alone or in combination with chemotherapy, are the standard of care in most …

Importance To date, no meta-analyses have comprehensively assessed the association of
neoadjuvant chemoimmunotherapy with clinical outcomes in non–small cell lung cancer …